| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Isolates of the Phytophthora fungus that infects potato crops are inhibited in their growth by metalaxyl (EC50s = 0.3-3.9 μg/mL) [1].
|
|---|---|
| ln Vivo |
In albinos, bradycardia was the result of metalaxyl therapy, and at the highest doses (250 and 300 mg/kg), bradycardia persisted and caused abrupt cardiac arrest. In hearts and mitochondria treated with metalaxyl, methanol cholinesterase activity does not develop [2].
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Metalaxyl has known human metabolites that include demethylmetalaxyl, Metalaxyl acid, 2-[(2,6-Dimethyl-3-hydroxyphenyl)(methoxyacetyl)amino]propionic acid methyl ester, and Methyl N-(2-(hydroxymethyl)-6-methylphenyl)-N-(methoxyacetyl)-DL-alanine. Three major and one minor metabolic pathways are proposed. One pathway involves hydrolysis of the ether, followed by oxidation of the resulting alcohol, ester hydrolysis, or N-dealkylation of the ester chain. A second pathway involves oxidation of an aromatic methyl to the benzylic acid or ester hydrolysis. The third major pathway is ester hydrolysis, sometimes followed by benzylic acid formation. The minor pathway involves hydroxylation at the meta position of the phenyl ring. The majority of urinary metabolites are conjugated (glucuronide or sulfate) whereas fecal metabolites are mostly unconjugated. The major metabolite in urine & feces is N-(2,6-dimethylphenyl)-N-(hydroxyacetyl) alanine. Metalaxyl is excreted in urine and the feces. (L918) |
| Toxicity/Toxicokinetics |
Toxicity Summary
Binds to nAChRs in nervous systems. It also causes endocrine disruption in humans by binding to and inhibiting the estrogen receptor. (T10, A590) Toxicity Data LD50: 669 mg/kg (Oral, Rat) (L918) LD50: 7120 mg/kg (Oral, hamster) (L918) LD50: >6000 mg/kg (Dermal, Rabbit) (L918) |
| References |
[1]. Emil Rekanović, et al. Toxicity of metalaxyl, azoxystrobin, dimethomorph, cymoxanil, zoxamide and mancozeb to Phytophthora infestans isolates from Serbia. J Environ Sci Health B. 2012;47(5):403-9.
[2]. K A Naidu, et al. Metalaxyl-induced bradycardia in rats: mediated by alpha-adrenoreceptors. J Toxicol Environ Health. 1988;23(4):495-8. |
| Additional Infomation |
Methyl N-(2,6-dimethylphenyl)-N-(methoxyacetyl)alaninate is an alanine derivative that is methyl alaninate in which one of the hydrogens attached to the nitrogen is substituted by a methoxyacetyl group, while the other is substituted by a 2,6-dimethylphenyl group. It is an alanine derivative, an aromatic amide, a carboxamide, an ether and a methyl ester.
Metalaxyl has been reported in Ganoderma lucidum with data available. (±)-Metalaxyl is a systemic agricultural fungicide belonging to the family of Depsipeptides. These are natural or synthetic compounds having sequences of amino and hydroxy carboxylic acid residues (usually I-amino and I-hydroxy acids), commonly but not necessarily regularly alternating. See also: Metalaxyl-M (annotation moved to). |
| Molecular Formula |
C15H21NO4
|
|---|---|
| Molecular Weight |
279.33
|
| Exact Mass |
279.147
|
| CAS # |
57837-19-1
|
| Related CAS # |
Metalaxyl-13C6;1356199-69-3;Metalaxyl-d6
|
| PubChem CID |
42586
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
394.3±42.0 °C at 760 mmHg
|
| Melting Point |
72-73°C
|
| Flash Point |
192.3±27.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| LogP |
2.15
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
20
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C[CH](N(C1=C(C)C=CC=C1C)C(COC)=O)C(OC)=O
|
| InChi Key |
ZQEIXNIJLIKNTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H21NO4/c1-10-7-6-8-11(2)14(10)16(13(17)9-19-4)12(3)15(18)20-5/h6-8,12H,9H2,1-5H3
|
| Chemical Name |
methyl 2-(N-(2-methoxyacetyl)-2,6-dimethylanilino)propanoate
|
| Synonyms |
CGA-48988; CGA 48988; Metalaxyl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~358.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5800 mL | 17.9000 mL | 35.7999 mL | |
| 5 mM | 0.7160 mL | 3.5800 mL | 7.1600 mL | |
| 10 mM | 0.3580 mL | 1.7900 mL | 3.5800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
